Novel phenotypic fluorescent three-dimensional platforms for high-throughput drug screening and personalized chemotherapy

Journal of Cancer

Volumn 4, Issue 5, 2013, Pages 401-415

  Fang, Changge ^a,b   Avis, Ingalill ^b   Salomon, David ^c   Cuttitta, Frank ^b  

^a Advanced Personalized Diagnostics LLC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Angiogenesis; Drug screening; Fluorescent; High throughput; Metastasis; Personalized chemotherapy; Three dimensional

Indexed keywords

BEVACIZUMAB; FUMAGILLIN; SUNITINIB; THALIDOMIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CAPILLARY DENSITY; CELL INTERACTION; CELL MIGRATION; CELL MOTION; CELL POPULATION; CINERADIOGRAPHY; CONTROLLED STUDY; DRUG SCREENING; DRUG SENSITIVITY; EXTRACELLULAR MATRIX; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RAT; TUMOR BIOPSY; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

EID: 84882959416     PISSN: None     EISSN: 18379664     Source Type: Journal    
DOI: 10.7150/jca.6780     Document Type: Article

References (50)

1. Albini A, Tosetti F, Li VW, Noonan DM, Li WW. Cancer prevention by targeting angiogenesis. Nat Rev Clin Oncol. 2012; 9: 498-509. doi:10.1038/nrclinonc.2012.120.
2. Kunz-Schughart LA, Freyer JP, Hofstaedter F, Ebner R. The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J Biomol Screen. 2004; 9: 273-85. doi:10.1177/1087057104265040.
3. Horning JL, Sahoo SK, Vijayaraghavalu S, Dimitrijevic S, Vasir JK, Jain TK, et al. 3-D tumor model for in vitro evaluation of anticancer drugs. Mol Pharm. 2008; 5: 849-62. doi:10.1021/mp800047v.
4. Pampaloni F, Reynaud EG, Stelzer EH. The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol. 2007; 8: 839-45. doi:nrm2236 [pii]. 10.1038/nrm2236.
5. Abbott A. Cell culture: biology's new dimension. Nature. 2003; 424: 870-2. doi:10.1038/424870a. 424870a [pii].
6. Smalley KS, Lioni M, Herlyn M. Life isn't flat: taking cancer biology to the next dimension. In Vitro Cell Dev Biol Anim. 2006; 42: 242-7. doi:0604027 [pii]. 10.1290/0604027.1.
7. Mitra M, Mohanty C, Harilal A, Maheswari UK, Sahoo SK, Krishnakumar S. A novel in vitro three-dimensional retinoblastoma model for evaluating chemotherapeutic drugs. Mol Vis. 2012; 18: 1361-78.
8. Friedrich J, Seidel C, Ebner R, Kunz-Schughart LA. Spheroid-based drug screen: considerations and practical approach. Nat Protoc. 2009; 4: 309-24. doi:nprot.2008.226 [pii]. 10.1038/nprot.2008.226.
9. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol. 1992; 3: 65-71.
10. Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992; 267: 10931-4.
11. Bissell MJ, Radisky D. Putting tumours in context. Nat Rev Cancer. 2001; 1: 46-54. doi:10.1038/35094059.
12. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420: 860-7. doi:10.1038/nature01322.
13. Xu F, Burk D, Gao Z, Yin J, Zhang X, Weng J, et al. Angiogenic deficiency and adipose tissue dysfunction are associated with macrophage malfunction in SIRT1-/- mice. Endocrinology. 2012; 153: 1706-16. doi:10.1210/en.2011-1667.
14. Petersen OW, Ronnov-Jessen L, Howlett AR, Bissell MJ. Interaction with basement membrane serves to rapidly distinguish growth and differentiation pattern of normal and malignant human breast epithelial cells. Proceedings of the National Academy of Sciences of the United States of America. 1992; 89: 9064-8.
15. Lang SH, Sharrard RM, Stark M, Villette JM, Maitland NJ. Prostate epithelial cell lines form spheroids with evidence of glandular differentiation in three-dimensional Matrigel cultures. British journal of cancer. 2001; 85: 590-9. doi:10.1054/bjoc.2001.1967.
16. Bianco C, Strizzi L, Ebert A, Chang C, Rehman A, Normanno N, et al. Role of human cripto-1 in tumor angiogenesis. J Natl Cancer Inst. 2005; 97: 132-41. doi:97/2/132 [pii]. 10.1093/jnci/dji011.
17. Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science. 1977; 197: 461-3.
18. Brown TA, Fetter RD, Tkachuk AN, Clayton DA. Approaches toward super-resolution fluorescence imaging of mitochondrial proteins using PALM. Methods. 2010; 51: 458-63. doi:10.1016/j.ymeth.2010.01.001.
19. Gimbrone MA, Jr., Leapman SB, Cotran RS, Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med. 1972; 136: 261-76.
20. Folkman J, Kalluri R. Cancer without disease. Nature. 2004; 427: 787. doi:10.1038/427787a. 427787a [pii].
21. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990; 82: 4-6.
22. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971; 285: 1182-6.
23. Folkman J. Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action. Exp Cell Res. 2006; 312: 594-607. doi:S0014-4827(05)00545-8 [pii]. 10.1016/j.yexcr.2005.11.015.
24. Folkman J, Haudenschild CC, Zetter BR. Long-term culture of capillary endothelial cells. Proc Natl Acad Sci U S A. 1979; 76: 5217-21.
25. Folkman J, Haudenschild C. Angiogenesis by capillary endothelial cells in culture. Trans Ophthalmol Soc U K. 1980; 100: 346-53.
26. Cukierman E, Pankov R, Stevens DR, Yamada KM. Taking cell-matrix adhesions to the third dimension. Science. 2001; 294: 1708-12. doi:10.1126/science.1064829.
27. Sporn MB. The war on cancer. Lancet. 1996; 347: 1377-81.
28. Sleeman JP, Nazarenko I, Thiele W. Do all roads lead to Rome? Routes to metastasis development. International journal of cancer Journal international du cancer. 2011; 128: 2511-26. doi:10.1002/ijc.26027.
29. Quatresooz P, Pierard-Franchimont C, Noel F, Pierard GE. Thigmotropism of malignant melanoma cells. Dermatol Res Pract. 2012; 2012: 362784. doi:10.1155/2012/362784.
30. Lee Y, El Andaloussi S, Wood MJ. Exosomes and microvesicles: extracellular vesicles for genetic information transfer and gene therapy. Human molecular genetics. 2012. doi:10.1093/hmg/dds317.
31. Ribatti D, Crivellato E. Immune cells and angiogenesis. J Cell Mol Med. 2009;13(9A):2822-33. doi: 10.1111/j.1582-4934.2009.00810.x.
32. Ribatti D, Crivellato E, Molica S. Mast cells and angiogenesis in haematological malignancies. Leuk Res. 2009; 33: 876-9. doi: 10.1016/j.leukres.2009.02.028.
33. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. The Journal of clinical investigation. 2003; 111: 1287-95. doi:10.1172/JCI17929.
34. Allt G, Lawrenson JG. Pericytes: cell biology and pathology. Cells Tissues Organs. 2001; 169: 1-11.
35. Kessler DA, Langer RS, Pless NA, Folkman J. Mast cells and tumor angiogenesis. Int J Cancer. 1976; 18: 703-9.
36. Ribatti D, Crivellato E. Mast cells, angiogenesis, and tumour growth. Biochimica et biophysica acta. 2012; 1822: 2-8. doi:10.1016/j.bbadis.2010.11.010.
37. Chan JK, Magistris A, Loizzi V, Lin F, Rutgers J, Osann K, et al. Mast cell density, angiogenesis, blood clotting, and prognosis in women with advanced ovarian cancer. Gynecol Oncol. 2005; 99: 20-5. doi:10.1016/j.ygyno.2005.05.042.
38. Wang XL, Fang JP, Tang RY, Chen XM. Different significance between intratumoral and peritumoral lymphatic vessel density in gastric cancer: a retrospective study of 123 cases. BMC Cancer. 2010; 10: 299. doi:10.1186/1471-2407-10-299.
39. Sutherland RM. Cell and environment interactions in tumor microregions: the multicell spheroid model. Science. 1988; 240: 177-84.
40. Furuya M, Yonemitsu Y, Aoki I. III. Angiogenesis: complexity of tumor vasculature and microenvironment. Curr Pharm Des. 2009; 15: 1854-67.
41. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007; 6: 273-86. doi:nrd2115 [pii]. 10.1038/nrd2115.
42. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996; 86: 353-64. doi:S0092-8674(00)80108-7 [pii].
43. Hanahan D, Christofori G, Naik P, Arbeit J. Transgenic mouse models of tumour angiogenesis: the angiogenic switch, its molecular controls, and prospects for preclinical therapeutic models. Eur J Cancer. 1996; 32A: 2386-93.
44. Knight ZA, Shokat KM. Chemical genetics: where genetics and pharmacology meet. Cell. 2007; 128: 425-30. doi:S0092-8674(07)00119-5 [pii]. 10.1016/j.cell.2007.01.021.
45. Chambers AF, Naumov GN, Vantyghem SA, Tuck AB. Molecular biology of breast cancer metastasis. Clinical implications of experimental studies on metastatic inefficiency. Breast Cancer Res. 2000; 2: 400-7.
46. Sleeman J, Steeg PS. Cancer metastasis as a therapeutic target. Eur J Cancer. 2010; 46: 1177-80. doi:S0959-8049(10)00166-8 [pii]. 10.1016/j.ejca.2010.02.039.
47. Barnhill RL, Lugassy C. Angiotropic malignant melanoma and extravascular migratory metastasis: description of 36 cases with emphasis on a new mechanism of tumour spread. Pathology. 2004; 36: 485-90. doi:10.1080/00313020412331282708. 2PL240DM9Y1X13JG [pii].
48. Elhammady MS, Manzano GR, Lebwohl N, Levi AD. Leiomyosarcoma metastases to the spine. Case series and review of the literature. J Neurosurg Spine. 2007; 6: 178-83. doi:10.3171/spi.2007.6.2.178.
49. Favier J, Plouin PF, Corvol P, Gasc JM. Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. The American journal of pathology. 2002; 161: 1235-46. doi:10.1016/S0002-9440(10)64400-8.
50. Samoto K, Ikezaki K, Ono M, Shono T, Kohno K, Kuwano M, et al. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer research. 1995; 55: 1189-93.